Therefore, we suggest that LND screening should be carried out in patients with intellectual disability, dystonic movement disorder and hyperuricemia, and the commercial HGPRT enzyme activity detection reagent can greatly improve the detection efficiency and reduce the screening cost. This evidence concerns the gene HPRT1 and Intellectual disability.